FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3148229635> ?p ?o ?g. }

• W3148229635 endingPage "1925" @default.
• W3148229635 startingPage "1916" @default.
• W3148229635 abstract "The key role of inflammation in the pathogenesis of coronary artery disease (CAD) is an urgent call for innovative treatments. Several trials have proposed colchicine as a therapeutic option for secondary prevention in CAD patients but its utilization is hampered by fears about drug-related adverse events (DAEs) and conflicting evidences. The aim of this meta-analysis was to consolidate evidence on the efficacy and safety of colchicine for secondary prevention in patients with CAD.A systematic search in electronic bibliographic databases of Medline, Scopus, Embase, and the Cochrane Library was performed to identify randomized controlled trials (RCTs) assessing the cardiovascular effects of colchicine in CAD patients, compared with placebo. Outcomes of interest were the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) and DAEs. Estimates were pooled using inverse-variance random-effects model. A total of 11 RCTs, including 12 869 patients, were identified as eligible. A total of 6501 patients received colchicine, while 6368 received placebo. After a median follow-up of 6 months (interquartile range, 1-16), patients receiving colchicine had a lower risk of MACCE [6% vs. 8.8%, relative risk (RR) = 0.67, 95% confidence interval (CI) 0.56-0.80, I2 = 19%], myocardial infarction (3.3% vs. 4.3%, RR = 0.76, 95% CI 0.61-0.96, I2 = 17%), coronary revascularization (2.9% vs. 4.2%, RR = 0.61, 95% CI 0.42-0.89, I2 = 40%), stroke (0.4% vs. 0.9%, RR = 0.48, 95% CI 0.30-0.77, I2 = 0%), hospitalization for cardiovascular cause (0.9% vs. 2.9%, RR = 0.32, 95% CI 0.12-0.87, I2 = 0%). Colchicine was associated with an increased risk of gastrointestinal DAEs (11% vs. 9.2%, RR = 1.67, 95% CI 1.20-2.34, I2 = 76%), myalgia (18% vs. 16%, RR = 1.16, 95% CI 1.02-1.32, I2 = 0%) and DAEs-related discontinuation (4.1% vs. 3%, RR = 1.54, 95% CI 1.02-2.32, I2 = 65%). However, gastrointestinal DAEs and discontinuation may be prevented with a lower daily dose. Colchicine did not increase the risk of cardiovascular death (0.7% vs. 1%, RR = 0.73, 95% CI 0.45-1.21, I2 = 14%), all-cause death (2% vs. 1.9%, RR = 1.01, 95% CI 0.71-1.43, I2 = 16%), or other DAEs.The use of colchicine in patients with CAD is safe and efficacious for MACCE prevention." @default.
• W3148229635 created "2021-04-13" @default.
• W3148229635 creator A5025250685 @default.
• W3148229635 creator A5028566075 @default.
• W3148229635 creator A5046197431 @default.
• W3148229635 creator A5050782259 @default.
• W3148229635 creator A5055478790 @default.
• W3148229635 creator A5085831794 @default.
• W3148229635 creator A5086228810 @default.
• W3148229635 date "2021-03-29" @default.
• W3148229635 modified "2023-09-30" @default.
• W3148229635 title "Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients" @default.
• W3148229635 cites W1153335416 @default.
• W3148229635 cites W1574489702 @default.
• W3148229635 cites W1893844572 @default.
• W3148229635 cites W2000793756 @default.
• W3148229635 cites W2008192823 @default.
• W3148229635 cites W2094941678 @default.
• W3148229635 cites W2095084942 @default.
• W3148229635 cites W2101640056 @default.
• W3148229635 cites W2104933371 @default.
• W3148229635 cites W2113978145 @default.
• W3148229635 cites W2121523819 @default.
• W3148229635 cites W2125435699 @default.
• W3148229635 cites W2128383347 @default.
• W3148229635 cites W2157786086 @default.
• W3148229635 cites W2166950143 @default.
• W3148229635 cites W2318373131 @default.
• W3148229635 cites W2419195245 @default.
• W3148229635 cites W2570248949 @default.
• W3148229635 cites W2748400555 @default.
• W3148229635 cites W2749050364 @default.
• W3148229635 cites W2783091713 @default.
• W3148229635 cites W2912019969 @default.
• W3148229635 cites W2913705661 @default.
• W3148229635 cites W2949696330 @default.
• W3148229635 cites W2952329033 @default.
• W3148229635 cites W2964952983 @default.
• W3148229635 cites W2983108401 @default.
• W3148229635 cites W2986700515 @default.
• W3148229635 cites W3003389325 @default.
• W3148229635 cites W3011371150 @default.
• W3148229635 cites W3016436366 @default.
• W3148229635 cites W3022903699 @default.
• W3148229635 cites W3033933095 @default.
• W3148229635 cites W3038763696 @default.
• W3148229635 cites W3081761942 @default.
• W3148229635 cites W3082109297 @default.
• W3148229635 cites W3082529560 @default.
• W3148229635 cites W3094055592 @default.
• W3148229635 cites W4288073614 @default.
• W3148229635 doi "https://doi.org/10.1093/eurjpc/zwab045" @default.
• W3148229635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33779702" @default.
• W3148229635 hasPublicationYear "2021" @default.
• W3148229635 type Work @default.
• W3148229635 sameAs 3148229635 @default.
• W3148229635 citedByCount "16" @default.
• W3148229635 countsByYear W31482296352021 @default.
• W3148229635 countsByYear W31482296352022 @default.
• W3148229635 countsByYear W31482296352023 @default.
• W3148229635 crossrefType "journal-article" @default.
• W3148229635 hasAuthorship W3148229635A5025250685 @default.
• W3148229635 hasAuthorship W3148229635A5028566075 @default.
• W3148229635 hasAuthorship W3148229635A5046197431 @default.
• W3148229635 hasAuthorship W3148229635A5050782259 @default.
• W3148229635 hasAuthorship W3148229635A5055478790 @default.
• W3148229635 hasAuthorship W3148229635A5085831794 @default.
• W3148229635 hasAuthorship W3148229635A5086228810 @default.
• W3148229635 hasConcept C119060515 @default.
• W3148229635 hasConcept C126322002 @default.
• W3148229635 hasConcept C127413603 @default.
• W3148229635 hasConcept C142724271 @default.
• W3148229635 hasConcept C164705383 @default.
• W3148229635 hasConcept C168563851 @default.
• W3148229635 hasConcept C197934379 @default.
• W3148229635 hasConcept C204787440 @default.
• W3148229635 hasConcept C27081682 @default.
• W3148229635 hasConcept C2776478404 @default.
• W3148229635 hasConcept C2778213512 @default.
• W3148229635 hasConcept C2780645631 @default.
• W3148229635 hasConcept C44249647 @default.
• W3148229635 hasConcept C500558357 @default.
• W3148229635 hasConcept C71924100 @default.
• W3148229635 hasConcept C78519656 @default.
• W3148229635 hasConcept C82789193 @default.
• W3148229635 hasConcept C95190672 @default.
• W3148229635 hasConceptScore W3148229635C119060515 @default.
• W3148229635 hasConceptScore W3148229635C126322002 @default.
• W3148229635 hasConceptScore W3148229635C127413603 @default.
• W3148229635 hasConceptScore W3148229635C142724271 @default.
• W3148229635 hasConceptScore W3148229635C164705383 @default.
• W3148229635 hasConceptScore W3148229635C168563851 @default.
• W3148229635 hasConceptScore W3148229635C197934379 @default.
• W3148229635 hasConceptScore W3148229635C204787440 @default.
• W3148229635 hasConceptScore W3148229635C27081682 @default.
• W3148229635 hasConceptScore W3148229635C2776478404 @default.
• W3148229635 hasConceptScore W3148229635C2778213512 @default.
• W3148229635 hasConceptScore W3148229635C2780645631 @default.

• next